Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

0.7440 -0.0286 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coherus Bio

< Previous 1 2 3 Next >
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces U.S. Launch of LOQTORZI™
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.